Avalo Therapeutics, Inc. Board of Directors

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Dr. Garry A. Neil M.D.

Dr. Garry A. Neil M.D.

Chairman of the Board, President & CEO

Dr. Dino C. Miano Ph.D.

Dr. Dino C. Miano Ph.D.

Senior Vice President of CMC & Technical Operations

Mr. Christopher Ryan Sullivan CPA

Mr. Christopher Ryan Sullivan CPA

CFO & Head of Investor relations

Dr. Lisa Hegg Ph.D.

Dr. Lisa Hegg Ph.D.

Senior Vice President of Program Management, Corporate Infrastructure & Clinical Operations

Dr. Barbara S. Slusher Ph.D.

Dr. Barbara S. Slusher Ph.D.

Founder and Member of Scientific Advisory Board

Dr. Solomon H. Snyder M.D.

Dr. Solomon H. Snyder M.D.

Founder and Chairman of Scientific Advisory Board

Ms. Colleen Matkowski

Ms. Colleen Matkowski

Senior Vice President of Global Regulatory Affairs & Quality Assurance

Ms. Jennifer Riley

Ms. Jennifer Riley

Chief Strategy Officer

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.